Literatur
Verwendete Literatur
Adams SC, DeLorey DS, Davenport MH, Farey AS, North S, Courneya KS (2018) Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer 118:1313–1321
Chau C, Cahtomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T (2015) Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. Ann Oncol 26:1865–1870
Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3):293–298. https://doi.org/10.7326/0003-4819-87-3-293
Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Stahl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S (2017) Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma. J Clin Oncol 35:194–200
Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Non-cancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533–544
Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB (2018) Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Adv Urol. https://doi.org/10.1155/2018/8671832
Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Jozwiak K, van den Belt-Dusebout AW, Gietema JA, Schaapveld M (2020) Platinum exposure and cause-specific mortality among patients with testicular cancer. Cancer 126:628–639
Hellesnes R, Kvammen Q, Myklebust TA, Brmnes RM, Karlsdottir A, Negaard HFS, Tandstad T, Wilsgaard T, Fossa SD, Haugnes HS (2020) Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer 147:21–32
Hellesnes R, Myklebust TA, Fossa SD, Bremnes RM, Karlsdottir A, Kvammen Q, Tandstad T, Wilsgaard T, Negaard HFS, Haugnes HS (2021) Testicular cancer in the cisplatin era: causes of death and mortaility rates in a population-based cohort. J Clin Oncol 39:3561–3573
Horwich A, Dearnaley DP, Sohaib A, Pennert K, Huddart RA (2013) Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol 24(8):2104–2107. https://doi.org/10.1093/annonc/mdt148
Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256–263
Liang F, Zhang S, Xue H, Chen Q (2017) Risk of second primary cancer in cancer patients treted with cisplatin: a systematic review and meta-analysis of randomized studies. BMC Cancer 17:871
Oliver RTD, Mead GM, Rustin GJS, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results of relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study. J Clin Oncol 29:957–962
Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickendorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Ziegler K, Haynes A, Jüni P, Kehl J, Gillessen S (2018) Baseline characteristics and pattterns of care in testicular cancer patients: first data from the Swiss Austrian German testicular cancer cohort study (SAG TCCS). Swiss Med Wkly 148:w14640
Schepisi G, De Padova S, De Lisi D, Casadei C, Meggiolaro E, Ruffilli F, Rosti G, Lolli C, Ravaglia G, Conteduca V, Farolfi A, Grassi L, De Giorgi U (2019) Psychosocial Issues in long-term survivors of testicular cancer. Front Endocrinol 10:113
Tandstad T, Stahl O, Dahl O, Haugnes HS, Hakansson U, Karlsdottir A, Kjellman A, Langber CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Stahl E, Wahlqvist R, Wall N, Cohn-Cedermark G (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian testicular cancer group (SWENOTECA). Ann Oncol 27:1299–1304
Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647
Weiterführende Literatur
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens, Kurzversion 1.0. https://www.leitlinienprogramm-onkologie.de/leitlinien/hodentumoren. Zugegriffen: 10. Apr. 2022 (AWMF-Registernummer: 043/049OL)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Papachristofilou und F. Zimmermann geben an, dass kein Interessenkonflikt besteht.
Additional information
Originalpublikation
Hellesnes R, Myklebust TA, Fossa SD et al (2021). Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. JCO. 39:3561–3573.
Rights and permissions
About this article
Cite this article
Papachristofilou, A., Zimmermann, F. Maligne Hodentumoren in der Cisplatin-Ära: Todesursachen und Letalität in einer Kohortenstudie. Strahlenther Onkol 198, 862–865 (2022). https://doi.org/10.1007/s00066-022-01957-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-022-01957-8